Anebulo is developing ANEB-001, a cannabinoid antagonist designed to reverse the effects of cannabinoid intoxication and improve outcomes for patients experiencing acute cannabis poisoning. This therapeutic addresses the rising incidence of emergency room visits due to unintentional cannabis overdose, particularly among vulnerable populations such as children.
Funding
Funding not disclosed
Founders
Product
Problem
Emergency room visits for cannabis intoxication are increasing, especially among children, due to the rising legalization of cannabis and the availability of edible products. There is currently no specific pharmacological treatment to reverse the effects of cannabinoid intoxication, leaving physicians with supportive care options only.
Solution
Anebulo Pharmaceuticals is developing ANEB-001, a cannabinoid receptor antagonist, to directly reverse the effects of acute cannabinoid intoxication. ANEB-001 aims to rapidly improve outcomes for patients experiencing cannabis overdose by competitively binding to cannabinoid receptors in the brain, displacing THC and other cannabinoids. By counteracting the psychoactive effects of cannabis, ANEB-001 seeks to alleviate symptoms such as anxiety, confusion, and impaired coordination, reducing the need for prolonged monitoring and hospitalization. The therapeutic is being developed to address the growing need for a targeted treatment option in emergency settings, particularly for vulnerable populations.
Target Audience
The primary target audience includes emergency room physicians and hospital systems treating patients with acute cannabis intoxication, as well as individuals and caregivers seeking a treatment option for cannabis overdose.
Features
- Cannabinoid receptor antagonist designed to competitively bind to CB1 receptors
- Intended to reverse the psychoactive effects of cannabis, such as anxiety and confusion
- Formulation suitable for rapid administration in emergency room settings
- Currently in preclinical and clinical development with ongoing Phase 1 and Phase 2 trials